产品说明书

Tenatoprazole

Print
Chemical Structure| 113712-98-4 同义名 : TU-199
CAS号 : 113712-98-4
货号 : A463838
分子式 : C16H18N4O3S
纯度 : 99%+
分子量 : 346.404
MDL号 : MFCD00929085
存储条件：

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 50 mg/mL(144.34 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • Proton Pump
描述 Tenatoprazole (TU-199) is an orally effective imidazopyridine-based proton pump inhibitor noted for its extended plasma half-life. It inhibits hog gastric H+/K+-ATPase activity with an IC50 of 6.2 μM and blocks the interaction between ubiquitin and the ESCRT-1 factor Tsg101, inhibiting the production of several enveloped viruses, including EBV[1].[2].[3].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00282555 Esophagitis, Reflux Phase 2 Suspended - Canada, Alberta ... 展开 >> Calgary, Alberta, Canada Edmonton, Alberta, Canada Canada, British Columbia Abbottsford, British Columbia, Canada Vancouver, British Columbia, Canada Canada, Manitoba Winnipeg, Manitoba, Canada Canada, Ontario Guelph, Ontario, Canada Hamilton, Ontario, Canada Scarborough, Ontario, Canada Toronto, Ontario, Canada Windsor, Ontario, Canada Canada, Quebec Lévis, Quebec, Canada Montreal, Quebec, Canada Pointe-Claire, Quebec, Canada Sherbrooke, Quebec, Canada St-Charles-de-Borromée, Quebec, Canada Canada, Saskatchewan Saskatoon, Saskatchewan, Canada Canada Quebec, Canada 收起 <<
NCT00284908 Esophagitis G... 展开 >>astroesophageal Reflux Stomach Ulcer Duodenal Ulcer 收起 << Phase 1 Completed - United States, Texas ... 展开 >> Healthcare Discoveries, Inc. San Antonio, Texas, United States, 78229 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.89mL

0.58mL

0.29mL

14.43mL

2.89mL

1.44mL

28.87mL

5.77mL

2.89mL
参考文献

[1]Thomson AB, et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther. 2006;23(8):1179-1187.

[2]Uchiyama K, et al. Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Methods Find Exp Clin Pharmacol. 1999;21(2):115-122.

[3]Mannemuddhu SS, et al. Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency. J Virol. 2021;95(13):e0246620.

[4]Uchiyama K, et al. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs. J Pharm Pharmacol. 1999;51(4):457-464.